Morningstar

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program Circle Pharma, Inc., a clinical-stage ...
Morningstar

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...
Business Wire

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming ...